The EDIL3 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the A2780 human ovarian cancer cell line, with targeted disruption of the EDIL3 gene. This loss-of-function model facilitates investigation of EDIL3 functions in angiogenesis, cell adhesion, and survival signaling in an epithelial ovarian carcinoma context.
The parental A2780 line, originating from an untreated patient with ovarian endometrioid adenocarcinoma, is extensively employed for cisplatin resistance, metastatic progression, and tumor biology studies. Its epithelial phenotype provides a relevant platform for exploring extracellular matrix contributions to ovarian cancer biology.
EDIL3 encodes an extracellular matrix glycoprotein that binds integrin receptors ??v??3 and ??v??5, activating FAK and downstream PI3K/AKT and NF-??B pathways. Upon ligand engagement, FAK phosphorylation recruits PI3K, generating PIP3 and leading to AKT activation, which in turn promotes survival and NF-??B-mediated transcription of BCL-2 and VEGF. This cascade enhances endothelial cell migration and suppresses apoptosis. EDIL3 transcription is stimulated by HIF-1??, VEGF, and Notch, establishing a pro-angiogenic feed-forward loop critical for tumor microenvironment remodeling.
In A2780 cells, EDIL3 augments ovarian cancer aggressiveness by mediating cell-ECM adhesion and paracrine angiogenic signaling. Disruption of EDIL3 in this polyclonal knockout population impairs integrin-mediated signaling, leading to reduced FAK/AKT pathway activity and diminished NF-??B-dependent transcription. Consequently, A2780 cells lacking EDIL3 may exhibit decreased cell adhesion, impaired migratory capacity, and compromised angiogenic paracrine signaling, making this model instrumental for studying tumor-stroma crosstalk and drug resistance.
Typical assays include western blotting and RT-qPCR to confirm knockout and assess downstream protein and mRNA changes, Sanger sequencing for genomic verification, endothelial tube formation assays to quantify angiogenic potential, cell adhesion assays on ECM substrates, transwell migration and invasion assays, phospho-FAK and phospho-AKT immunoblotting, and apoptosis assays using Annexin V staining. This polyclonal population is particularly suited for investigating ovarian cancer angiogenesis, testing anti-angiogenic therapies, and exploring combination strategies to overcome platinum resistance. For further details or custom gene editing services, contact Ascent Research.
